Figure 2.
PFS and OS with single-agent ibrutinib treatment. (A) PFS in the total efficacy population and by prior line of therapy. (B) OS in the total efficacy population and by prior line of therapy.
PFS and OS with single-agent ibrutinib treatment. (A) PFS in the total efficacy population and by prior line of therapy. (B) OS in the total efficacy population and by prior line of therapy.